The average one-year price target for GLENMARK PHARMACEUTICALS (NSE:GLENMARK) has been revised to 594.15 / share. This is an increase of 15.58% from the prior estimate of 514.08 dated May 10, 2023.
Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) outperformed the Pharmaceuticals industry on the basis of its ROE – producing a higher 11.78% relative to the peer average of 11.47% over the past 12 ...
Capital Market on MSN
Glenmark Pharmaceuticals Ltd soars 0.2%, gains for fifth straight session
Glenmark Pharmaceuticals Ltd is up for a fifth straight session today. The stock is quoting at Rs 1979, up 0.2% on the day as ...
Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic ...
Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic ...
Reuters Market Eye - Shares in Glenmark Pharmaceuticals (NSI:GLENMARK.NS - News), GlaxoSmithKline Consumer Healthcare (NSI:GSKCONS.NS - News) and United Breweries Ltd (NSI:UBL.NS - News) gain after ...
Shares of drug maker Glenmark Pharma witnessed rise on Thursday (19 May) on both BSE and NSE after the company said that it has received the final approval from the US Food and Drug Administration for ...
(RTTNews) - Glenmark Pharmaceuticals Inc., USA, affiliated to India-based Glenmark Pharmaceuticals Ltd., announced Tuesday the launch of Vancomycin Hydrochloride for Injection USP in single-dose vials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback